We advised the sales agent on the offering

Davis Polk advised Leerink Partners LLC as the sales agent in connection with a new SEC-registered at-the-marketing offering program by Oculis Holding AG under which Oculis Holding may sell up to an aggregate amount of $100 million ordinary shares. Oculis Holding’s ordinary shares are traded on the Nasdaq Global Market and the Nasdaq Iceland Main Market under the symbol “OCS.”

Oculis is a global late clinical-stage biopharmaceutical company, headquartered in Switzerland with operations in Switzerland, the United States and Iceland. It has substantial expertise in therapeutics for the treatment of neuro-ophthalmic and ophthalmic diseases. It is engaged in developing innovative drug candidates that embrace the potential to address significant unmet medical needs.

The Davis Polk corporate team included partner Derek Dostal and associate Nicole Hylas. The tax team included counsel Yixuan Long and associate Benjamin Silver. All members of the Davis Polk team are based in the New York office.

Copy link to share post